Pulmonx Corp
NASDAQ:LUNG
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
Market Cap | EV/EBIT | ||||
---|---|---|---|---|---|
US |
Pulmonx Corp
NASDAQ:LUNG
|
369.9m USD | -4.8 | ||
JP |
Hoya Corp
TSE:7741
|
6.4T JPY | 28.6 | ||
CH |
Alcon AG
SIX:ALC
|
36.1B CHF | 37 | ||
DK |
Coloplast A/S
CSE:COLO B
|
189.1B DKK | 29.8 | ||
US |
Align Technology Inc
NASDAQ:ALGN
|
20.2B USD | 31.1 | ||
US |
Cooper Companies Inc
NYSE:COO
|
18.4B USD | 39.5 | ||
KR |
H
|
HLB Inc
KOSDAQ:028300
|
13.9T KRW | -110.4 | |
CN |
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
61.5B CNY | 32.6 | ||
UK |
ConvaTec Group PLC
LSE:CTEC
|
5.3B GBP | 50.9 | ||
US |
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
5.8B USD | 26.1 | ||
US |
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.3B USD | 10.8 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.